Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction (STADIA-HFpEF)

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. A 35-week, Single-center, Prospective, Double-blind, Controlled, Randomized, 2x2 Crossover, Interventional Phase II Study, Investigating the Effect of Treatment With Dapagliflozin 10mg od on Left Ventricular Distensibility in Patients With Early HFpEF.

A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover, interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg od on Left Ventricular distensibility in patients with early HFpEF.

Study Overview

• Status: Unknown
• Conditions: Heart Failure, Diastolic
• Intervention / Treatment: Drug: Placebo; Drug: Dapagliflozin

• Study Type: Interventional
• Enrollment (Anticipated): 26
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Marielle Scheffer, MD; Phone Number: 0031205994889; Email: mailcardio.research@olvg.nl

Study Locations

• Netherlands
  • Noord-Holland
    • Amsterdam, Noord-Holland, Netherlands, 1091
      • Recruiting
      • OLVG
      • Contact: Marielle Scheffer; Phone Number: 0031205994889; Email: mailcardio.research@olvg.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age ≥ 18 years at time of screening

2. Symptomatic chronic heart failure patients with diagnosis of heart failure and:

   • NYHA class II-IV
   • Preserved systolic Left Ventricular (LV) function, defined by: LV Ejection Fraction (LVEF) ≥ 50% and LV end-diastolic volume index <97 ml/m2

   • Evidence of diastolic LV dysfunction and at least 1 out of the 5 following additional criteria:

     1. H2FPEF score ≥ 6;
     2. HFA-PEFF score ≥ 5;
     3. Pulmonary capillary wedge pressure > 15 mmHg at rest or > 25 mmHg with exercise assessed with right heart catheterization;
3. Cardiac MRI T1 derived extracellular volume <29% at screening
4. Oral diuretics, if prescribed to the patient according to local guidelines and at the discretion of the investigator, should be stable for at least 1 week prior to baseline visit
5. Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial

Exclusion Criteria:

1. Reduced systolic LV function (LVEF < 50%), measured at any time point in the history of the patient
2. Obstructive coronary artery disease with evidence of ischemia
3. Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days prior to screening visit
4. More than mild valve stenosis
5. More than moderate aortic and/or mitral valve regurgitation
6. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. hemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (stress cardiomyopathy), hypertrophic (obstructive) cardiomyopathy or known pericardial constriction
7. History of mitral valve repair or replacement
8. Atrial fibrillation or atrial flutter with a resting heart rate > 110 bpm at screening
9. Acute decompensation that requires intravenous loop diuretics
10. Systolic blood pressure ≥ 180 mmHg. If SBP > 150 mmHg and < 180 mmHg, the patient should be receiving at least 3 antihypertensive drugs at screening or baseline visit
11. Symptomatic hypotension and/or a SBP < 100 mmHg at screening or baseline visit
12. Impaired renal function, defined as eGFR < 30 ml/min/1.73 m2
13. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal or history of cirrhosis with evidence of portal hypertension
14. Hemoglobin < 9 g/dl at screening
15. Chronic obstructive pulmonary disease, more than GOLD class 2
16. Pulmonary function test with FEV1/FVC < 80%
17. Primary pulmonary arterial hypertension
18. Type 1 Diabetes Mellitus
19. History of ketoacidosis
20. Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or low risk prostate cancer (biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a)
21. Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor within 3 months prior to screening visit. Discontinuation of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor for the purposes of study enrolment is not permitted
22. Pregnancy or lactation
23. Any (clinical) condition that, in the investigator's opinion, would jeopardize patients safety while participating in this trial, or may prevent the patient from adhering to the trial protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Group A; Dapagliflozin - washout period - placebo	Drug: Placebo; Placebo; Drug: Dapagliflozin; 10mg od
ACTIVE_COMPARATOR: Group B; Placebo - washout period - Dapagliflozin	Drug: Placebo; Placebo; Drug: Dapagliflozin; 10mg od

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Left Ventricular (LV) e'	echocardiographically measured	13 weeks
E/e'/LV end-diastolic volume index	echocardiographically measured	13 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kansas City Cardiomyopathy Questionnaire		13 weeks
6-minute walk test		13 weeks
Left atrial volume	Echocardiographically derived volume	13 weeks
Diastolic parameters	Echocardiographically derived function, filling and compliance of Left Ventricular	13 weeks
Left atrial function	Echocardiographically derived strain analysis, resevoir, conduit and booster pump function	13 weeks

Collaborators and Investigators

• Sponsor: Mariëlle Scheffer
• Collaborators: AstraZeneca

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 1, 2020
• Primary Completion (ANTICIPATED): November 1, 2021
• Study Completion (ANTICIPATED): May 1, 2022

Study Registration Dates

• First Submitted: July 8, 2020
• First Submitted That Met QC Criteria: July 16, 2020
• First Posted (ACTUAL): July 17, 2020

Study Record Updates

• Last Update Posted (ACTUAL): September 22, 2020
• Last Update Submitted That Met QC Criteria: September 18, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Heart Failure, Diastolic; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Sodium-Glucose Transporter 2 Inhibitors; Dapagliflozin
• Other Study ID Numbers: 19.185

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No